ArticleInternational dental journal2026
SHED-Derived Exosomes Attenuate Osteoclastogenesis to Ameliorate Apical Periodontitis in Rats.
Article in International dental journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION AND
aimsApical periodontitis (AP) is a prevalent oral disease characterized by periapical tissue inflammation and alveolar bone resorption. This study investigated the inhibitory effects of human exfoliated deciduous teeth-derived exosomes (SHED-EXOs) on osteoclastogenesis, elucidated the underlying mechanisms, and evaluated their protect efficacy in AP rat models, aiming to provide novel adjunctive therapies to augment root canal treatment.
methodsIn vitro, bone marrow-derived monocytes (BMMs) underwent osteoclastogenesis were cultured with graded concentrations of SHED-EXOs (0-20 μg/mL). Tartrate-resistant acid phosphatase staining and podosome belt immunofluorescence assays were performed to assess osteoclast formation. Osteoclast-related protein and gene expression were quantified. Exosomal proteomics and osteoclast transcriptomic sequencing were integrated with bioinformatic analysis to identify pivotal signalling pathways. In vivo, AP rat model were developed and received localized intrapulpal delivery of hydrogel-encapsulated SHED-EXOs. The therapeutic efficacy was evaluated through micro-CT, histological staining, and immunohistochemical analysis.
resultsSHED-EXOs concentration-dependently suppressed osteoclast formation with downregulation of NFATC1/CTSK/RANKL. Multiomics analysis revealed enrichment of PI3K-AKT signalling, and mechanistically, SHED-EXOs may inhibit osteoclastogenesis by activating PI3K-AKT pathway. In vivo, local delivery of SHED-EXOs via hydrogel significantly reduced the number of osteoclasts, decreased the expression of NFATC1 as well as RANKL, activated PI3K-AKT signalling, attenuated bone resorption, and restored periapical structure.
conclusionSHED-EXOs may serve as a promising cell-free adjunctive strategy for AP, inhibiting osteoclasts potentially via PI3K-AKT activation. CLINICAL RELEVANCE: This study developed a novel cell-free therapeutic strategy based on SHED-EXOs to enhance the treatment efficacy for AP. SHED-EXOs effectively inhibit osteoclast activity, attenuate bone resorption, and promote periapical bone tissue repair. The underlying mechanism involves the activation of the PI3K-AKT pathway. Combined with a localized hydrogel delivery system, this strategy paves the way for innovative approaches in regenerative endodontics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.